Urteste S.A. enrolls the first patient in the Panuri test clinical study
Urteste S.A. enrolled the first patient in the Panuri pancreatic cancer study; interim analysis results are expected in Q4 2026.
Urteste S.A. enrolled the first patient in the Panuri pancreatic cancer study; interim analysis results are expected in Q4 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.